Literature DB >> 23355336

Molecular diagnosis and prognostic significance of lymph node micrometastasis in patients with histologically node-negative non-small cell lung cancer.

Chun-Hua Dai1, Jian Li, Li-Chao Yu, Xia-Qin Li, Shun-Bing Shi, Jian-Rong Wu.   

Abstract

Lymph node metastasis is a major prognostic factor in resected non-small cell lung cancer (NSCLC). However, 30-40 % rate of recurrence after performing complete resection in node-negative patients suggests that their nodal staging is suboptimal. We aimed to evaluate the molecular diagnosis and prognostic significance of lymph node micrometastasis in patients with node-negative NSCLC. Primary tumor samples from 62 patients with resected stage I-IIB NSCLC were screened for fragile histidine triad (FHIT) and CDKN2A mRNA deletion using reverse transcriptase polymerase chain reaction (RT-PCR). The molecular alternations were found in tumors of 49 patients. A total of 269 lymph nodes from these 49 NSCLC patients with FHIT or/and CDKN2A deletion tumors were examined. Fifteen positive-control nodes and ten negative-control nodes were also analyzed for FHIT and CDKN2A mRNA deletion. Thirty-nine (22 %) and 22 (18 %) lymph nodes from the 49 patients with FHIT and CDKN2A mRNA deletion in primary tumor had FHIT and CDKN2A mRNA deletion, respectively. The types of FHIT and CDKN2A mRNA deletion in lymph nodes were identical with those in their primary tumors. By combination of two markers, 16 patients (32.7 %) were found to have nodal micrometastasis. Survival analysis showed that patients with nodal micrometastasis had reduced disease-free survival (P = 0.001) and overall survival (P = 0.002) rates. Multivariate analysis demonstrated that nodal micrometastasis was an independent predictor for worse prognosis. Thus, the detection of lymph node micrometastasis by FHIT and CDKN2A mRNA deletion RT-PCR will be helpful to predict the recurrence and prognosis of patients with completely resected stage I-IIB NSCLC.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23355336     DOI: 10.1007/s13277-013-0667-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  32 in total

1.  Prognostic value of genetically diagnosed lymph node micrometastasis in non-small cell lung carcinoma cases.

Authors:  T Hashimoto; Y Kobayashi; Y Ishikawa; S Tsuchiya; S Okumura; K Nakagawa; Y Tokuchi; M Hayashi; K Nishida; S Hayashi; J Hayashi; E Tsuchiya
Journal:  Cancer Res       Date:  2000-11-15       Impact factor: 12.701

2.  Can tumor size be a guide for limited surgical intervention in patients with peripheral non-small cell lung cancer? Assessment from the point of view of nodal micrometastasis.

Authors:  Y Ohta; M Oda; J Wu; Y Tsunezuka; M Hiroshi; A Nonomura; G Watanabe
Journal:  J Thorac Cardiovasc Surg       Date:  2001-11       Impact factor: 5.209

Review 3.  FHIT as tumor suppressor: mechanisms and therapeutic opportunities.

Authors:  Yuri Pekarsky; Alexey Palamarchuk; Kay Huebner; Carlo M Croce
Journal:  Cancer Biol Ther       Date:  2002 May-Jun       Impact factor: 4.742

4.  Role of FHIT in human cancer.

Authors:  C M Croce; G Sozzi; K Huebner
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

5.  Detection of disseminated tumor cells in mediastinoscopic lymph node biopsies and lymphadenectomy specimens of patients with NSCLC by quantitative RT-PCR.

Authors:  Xiao Tao Wang; Wulf Sienel; Stephan Eggeling; Corina Ludwig; Erich Stoelben; Johannes Mueller; Christoph A Klein; Bernward Passlick
Journal:  Eur J Cardiothorac Surg       Date:  2005-07       Impact factor: 4.191

6.  Quantitative real-time polymerase chain reaction detection of lymph node lung cancer micrometastasis using carcinoembryonic antigen marker.

Authors:  Mario Nosotti; Monica Falleni; Alessandro Palleschi; Caterina Pellegrini; Francesca Alessi; Silvano Bosari; Luigi Santambrogio
Journal:  Chest       Date:  2005-09       Impact factor: 9.410

7.  Aberrant p16 promoter methylation in smokers and former smokers with nonsmall cell lung cancer.

Authors:  Sonata Jarmalaite; Annamaria Kannio; Sisko Anttila; Juozas R Lazutka; Kirsti Husgafvel-Pursiainen
Journal:  Int J Cancer       Date:  2003-10-10       Impact factor: 7.396

8.  Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers.

Authors:  J G Herman; A Merlo; L Mao; R G Lapidus; J P Issa; N E Davidson; D Sidransky; S B Baylin
Journal:  Cancer Res       Date:  1995-10-15       Impact factor: 12.701

9.  Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project.

Authors:  Carla Verri; Luca Roz; Davide Conte; Triantafillos Liloglou; Anna Livio; Aurelien Vesin; Alessandra Fabbri; Francesca Andriani; Christian Brambilla; Luca Tavecchio; Giuseppe Calarco; Elisa Calabrò; Andrea Mancini; Diego Tosi; Paolo Bossi; John K Field; Elisabeth Brambilla; Gabriella Sozzi
Journal:  Am J Respir Crit Care Med       Date:  2008-12-18       Impact factor: 21.405

10.  Lymph node isolated tumor cells and micrometastases in pathological stage I non-small cell lung cancer: prognostic significance.

Authors:  Ottavio Rena; Luca Carsana; Silvia Cristina; Esther Papalia; Fabio Massera; Luca Errico; Cristina Bozzola; Caterina Casadio
Journal:  Eur J Cardiothorac Surg       Date:  2007-11-01       Impact factor: 4.191

View more
  13 in total

1.  Occult pN2 disease in lung cancer patients: a wide range of diseases endangering the long term prognosis.

Authors:  Marc Riquet; Ciprian Pricopi; Giuseppe Mangiameli; Alex Arame; Alain Badia; Françoise Le Pimpec Barthes
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

Review 2.  Current innovations in sentinel lymph node mapping for the staging and treatment of resectable lung cancer.

Authors:  Krista J Hachey; Yolonda L Colson
Journal:  Semin Thorac Cardiovasc Surg       Date:  2014-09-16

3.  Comparison of recurrence risk between patients with clinically node-positive and -negative stage I non-small cell lung cancer following surgery: A propensity score matching analysis.

Authors:  Kuo-Yang Huang; Hung-Jen Chen; Ching-Hsiung Lin; Bing-Yen Wang; Ching-Yuan Cheng; Sheng-Hao Lin
Journal:  Thorac Cancer       Date:  2022-05-17       Impact factor: 3.223

4.  Detection of occult tumor cells in regional lymph nodes is associated with poor survival in pN0 non-small cell lung cancer: a meta-analysis.

Authors:  Zhicheng He; Yang Xia; Shaowen Tang; Yijiang Chen; Liang Chen
Journal:  J Thorac Dis       Date:  2016-03       Impact factor: 2.895

5.  The clinical value of a new method of functional lymph node dissection in video-assisted thoracic surgery right non-small cell lung cancer radical resection.

Authors:  Sui Chen; Shijie Huang; Shaobin Yu; Ziyang Han; Lei Gao; Zhimin Shen; Mingqiang Kang
Journal:  J Thorac Dis       Date:  2019-02       Impact factor: 2.895

6.  Longitudinal study on circulating miRNAs in patients after lung cancer resection.

Authors:  Petra Leidinger; Valentina Galata; Christina Backes; Cord Stähler; Stefanie Rheinheimer; Hanno Huwer; Eckart Meese; Andreas Keller
Journal:  Oncotarget       Date:  2015-06-30

Review 7.  Prognostic factors in resected lung carcinomas.

Authors:  Keith M Kerr; Marianne C Nicolson
Journal:  EJC Suppl       Date:  2013-09

8.  Using logistic regression to improve the prognostic value of microarray gene expression data sets: application to early-stage squamous cell carcinoma of the lung and triple negative breast carcinoma.

Authors:  David W Mount; Charles W Putnam; Sara M Centouri; Ann M Manziello; Ritu Pandey; Linda L Garland; Jesse D Martinez
Journal:  BMC Med Genomics       Date:  2014-06-10       Impact factor: 3.063

9.  Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer.

Authors:  Ane Kongsgaard Rud; Kjetil Boye; Øystein Fodstad; Siri Juell; Lars H Jørgensen; Steinar Solberg; Åslaug Helland; Odd Terje Brustugun; Gunhild Mari Mælandsmo
Journal:  Diagn Pathol       Date:  2016-06-17       Impact factor: 2.644

10.  Prognostic value of molecular events from negative surgical margin of non-small-cell lung cancer.

Authors:  Bangrong Cao; Lin Feng; Dan Lu; Yan Liu; Yu Liu; Suping Guo; Naijun Han; Xiangyang Liu; Yousheng Mao; Jie He; Shujun Cheng; Yanning Gao; Kaitai Zhang
Journal:  Oncotarget       Date:  2016-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.